MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598058 | Name: Allotrap

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Allotrap is a small synthetic peptide derived from the alpha1 helix of the heavy chain of HLA class I proteins; inhibits human T cell responses in vitro; prolongs allograft survival in rats and mice.

Chemical Structure

Allotrap
Allotrap
CAS#151232-75-6

Theoretical Analysis

MedKoo Cat#: 598058

Name: Allotrap

CAS#: 151232-75-6

Chemical Formula: C53H90N20O16

Exact Mass: 1262.6844

Molecular Weight: 1263.42

Elemental Analysis: C, 50.39; H, 7.18; N, 22.17; O, 20.26

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Allotrap; Peptide Bc-1nl;
IUPAC/Chemical Name
(2S,8S,11S,14S,17S,20S,23S,26S)-14-(2-amino-2-oxoethyl)-26-((S)-2-amino-5-guanidinopentanamido)-8,17-bis(3-guanidinopropyl)-2-(4-hydroxybenzyl)-23-(hydroxymethyl)-11,20-diisobutyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazanonacosanedioic acid
InChi Key
KXASYRUYKYOKGG-IWLMWFOOSA-N
InChi Code
InChI=1S/C53H90N20O16/c1-26(2)20-34(46(84)68-31(9-6-18-63-52(58)59)43(81)65-24-40(77)66-37(50(88)89)22-28-11-13-29(75)14-12-28)70-48(86)36(23-39(55)76)72-44(82)32(10-7-19-64-53(60)61)69-47(85)35(21-27(3)4)71-49(87)38(25-74)73-45(83)33(15-16-41(78)79)67-42(80)30(54)8-5-17-62-51(56)57/h11-14,26-27,30-38,74-75H,5-10,15-25,54H2,1-4H3,(H2,55,76)(H,65,81)(H,66,77)(H,67,80)(H,68,84)(H,69,85)(H,70,86)(H,71,87)(H,72,82)(H,73,83)(H,78,79)(H,88,89)(H4,56,57,62)(H4,58,59,63)(H4,60,61,64)/t30-,31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
SMILES Code
OC1=CC=C(C=C1)C[C@@H](C(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,263.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tice DG, Bruch D, Buelow R, Squiers EC. Survival of rat small bowel allografts treated with allotrap 07R. J Surg Res. 1997 Sep;72(1):78-83. PubMed PMID: 9344717. 2: Iyer S, Kontoyiannis D, Chevrier D, Woo J, Mori N, Cornejo M, Kollias G, Buelow R. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem. 2000 Jun 2;275(22):17051-7. PubMed PMID: 10748117. 3: Buelow R, Veyron P, Clayberger C, Pouletty P, Touraine JL. Prolongation of skin allograft survival in mice following administration of ALLOTRAP. Transplantation. 1995 Feb 27;59(4):455-60. PubMed PMID: 7878745. 4: Oberyszyn TM, Robertson FM, Tober KL, Ross MS, Parrett ML, Wilgus TA, Iyer S, Woo J, Buelow R. Inhibition of cutaneous UV light-induced tumor necrosis factor-alpha protein production by Allotrap 1258, a novel immunomodulatory peptide. Photochem Photobiol. 2001 Feb;73(2):184-90. PubMed PMID: 11272733. 5: Gao L, Woo J, Buelow R. Both L- and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice. J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):78-87. PubMed PMID: 8820086. 6: Li W, Iyer S, Lu L, Buelow R, Fung JJ, Rao AS, Woo J, Qian S. Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int. 2003 Dec;16(12):849-56. Epub 2003 Aug 27. PubMed PMID: 12942166. 7: Squiers EC, Hodell M, Beulow R. Allotrap prolongs survival of porcine islet xenografts in diabetic mice. Transplant Proc. 1997 Jun;29(4):2168-9. PubMed PMID: 9193574. 8: Masroor S, Itescu S, Artrip JH, Minanov OP, Buelow R, Michler RE. Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A. Ann Thorac Surg. 1998 Jan;65(1):144-8. PubMed PMID: 9456108. 9: Yu X, Song B, Huang C, Xiao Y, Fang M, Feng J, Wang P, Zhang G. Prolonged survival time of allografts by the oral administration of RDP58 linked to the cholera toxin B subunit. Transpl Immunol. 2012 Oct;27(2-3):122-7. doi: 10.1016/j.trim.2012.06.004. Epub 2012 Jun 15. PubMed PMID: 22709942. 10: Tice DG, Bruch D, Squiers EC. Graft survival and MLC response in LEW-ACI small bowel transplants treated with a novel MHC peptide, BC-1nl. Transplant Proc. 1998 Sep;30(6):2590-1. PubMed PMID: 9745504. 11: Iyer S, Lahana R, Buelow R. Rational design and development of RDP58. Curr Pharm Des. 2002;8(24):2217-29. Review. PubMed PMID: 12369864. 12: Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ; RDP Investigators Study Group. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005 Aug;11(8):713-9. PubMed PMID: 16043985. 13: Clayberger C, Krensky AM. Immunosuppressive peptides corresponding to MHC class I sequences. Curr Opin Immunol. 1995 Oct;7(5):644-8. Review. PubMed PMID: 8573307. 14: Hoffmann JC. [Inflammatory bowel disease: anti-TNF strategies and beyond]. Dtsch Med Wochenschr. 2004 Sep 3;129 Suppl 2:S76-8. German. PubMed PMID: 15368175. 15: Murthy S, Flanigan A, Coppola D, Buelow R. RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31. PubMed PMID: 12540016. 16: Holtmann MM. RDP-58 (SangStat Medical). IDrugs. 2003 Dec;6(12):1188-94. Review. PubMed PMID: 14666431. 17: Boismenu R, Chen Y, Chou K, El-Sheikh A, Buelow R. Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii19-24. PubMed PMID: 12379615; PubMed Central PMCID: PMC1766705. 18: Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec;5(6):518-23. Review. PubMed PMID: 14602063. 19: DeVry CG, Valdez M, Gao L, Wang J, Kotsch K, Volk HD, Bechmann I, Buelow R, Iyer S. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004 Jul;152(1-2):33-43. PubMed PMID: 15223235. 20: De Vry CG, Valdez M, Lazarov M, Muhr E, Buelow R, Fong T, Iyer S. Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol. 2005 Sep;125(3):473-81. PubMed PMID: 16117788.